Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study

被引：0
|
作者：
Cicardi, M. [1 ]
Shennak, M. [2 ]
Zaragoza-Urdaz, R. H. [3 ]
Wang, Y. [4 ]
Lu, P. [4 ]
机构：
[1] Univ Milan, Dept Biomed & Clin Sci, ASST Fatebenefratelli Sacco, Luigi Sacco, Milan, Italy
[2] Triumpharma, Amman, Jordan
[3] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA
[4] Shire, Lexington, MA USA
来源：
ALLERGY | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
1428
引用
收藏
页码：722 / 722
页数：1
相关论文
共 50 条
  • [1] Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study
    Bernstein, J. A.
    Banerji, A.
    Schranz, J.
    Nurse, C.
    Riedl, M.
    Lu, P.
    ALLERGY, 2018, 73 : 288 - 289
  • [2] Consistent Lanadelumab Treatment Effect In Patients With Hereditary Angioedema (HAE) Regardless Of Baseline Attack Frequency In The Phase 3 HELP Study
    Riedl, Marc A.
    Tachdjian, Raffi
    Schranz, Jennifer
    Nurse, Christina
    Bernstein, Jonathan A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB47 - AB47
  • [3] Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP Study
    Maurer, M.
    Gierer, S.
    Hebert, J.
    Hao, J.
    Lu, P.
    Bruelle, J.
    Banerji, A.
    SWISS MEDICAL WEEKLY, 2018, 148 : 36S - 36S
  • [4] Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): Results of the phase 3 HELP study
    Maurer, M.
    Gierer, S.
    Hebert, J.
    Hao, J.
    Lu, P.
    Banerji, A.
    ALLERGY, 2018, 73 : 289 - 289
  • [5] Efficacy of lanadelumab in patients with HAE is independent of body mass index: Findings from the HELP study
    Zanichelli, A.
    Hebert, J.
    Soteres, D.
    Hao, J.
    Lu, P.
    Busse, P.
    ALLERGY, 2018, 73 : 722 - 723
  • [6] High responder rates in lanadelumab-treated patients in the phase 3 HELP study
    Maurer, M.
    Davis-Lorton, M.
    Schranz, J.
    Hao, J.
    Busse, P. J.
    ALLERGY, 2018, 73 : 289 - 290
  • [7] Lanadelumab And Cardiovascular Risk: Findings From The Phase 3 HELP Study
    Sexton, Daniel J.
    Brown, Nancy J.
    Lumry, William R.
    Gower, Richard G.
    Hao, James
    Lu, Peng
    Zafra, Heidi T. V.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB46 - AB46
  • [8] LANADELUMAB SAFETY AND IMMUNOGENICITY: RESULTS FROM THE PHASE 3 HELP STUDY
    Johnston, D.
    Banerji, A.
    Riedl, M.
    Zuraw, B.
    Lumry, W.
    Bernstein, J.
    Li, H.
    Lu, P.
    Hao, J.
    Gower, R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S36 - S36
  • [9] RELEVANCE OF PLASMA KALLIKREIN (PKAL) LEVELS FOR LANADELUMAB PHARMACOKINETICS (PK) IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE).
    Ahmed, M.
    Wang, Y.
    Zhu, A.
    Sexton, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S5 - S6
  • [10] Attack-Free Status of Patients With Hereditary Angioedema (HAE) During Extended Treatment With Lanadelumab in the HELP OLE Study
    Riedl, Marc
    Johnston, Douglas
    Lumry, William
    Bernstein, Jonathan
    Nurse, Christina
    Lu, Peng
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB104 - AB104
12345